Vertex Pharmaceuticals Enters Material Definitive Agreement
Ticker: VRTX · Form: 8-K · Filed: Aug 16, 2024 · CIK: 875320
Sentiment: neutral
Topics: material-agreement
Related Tickers: VRTX
TL;DR
VRTX signed a big deal, details TBD.
AI Summary
On August 15, 2024, Vertex Pharmaceuticals Incorporated entered into a material definitive agreement. The filing does not disclose the specific details of this agreement, such as the counterparty or the financial implications.
Why It Matters
This filing indicates a significant new development for Vertex Pharmaceuticals, potentially involving partnerships, acquisitions, or licensing deals that could impact its future growth and product pipeline.
Risk Assessment
Risk Level: medium — The lack of specific details in the filing creates uncertainty about the nature and impact of the agreement.
Key Players & Entities
- Vertex Pharmaceuticals Incorporated (company) — Registrant
- August 15, 2024 (date) — Date of earliest event reported
FAQ
What is the nature of the material definitive agreement entered into by Vertex Pharmaceuticals?
The filing does not specify the nature of the agreement, only that a material definitive agreement was entered into on August 15, 2024.
Who is the counterparty to this material definitive agreement?
The filing does not disclose the name of the other party involved in the agreement.
What are the financial terms or implications of this agreement?
The filing does not provide any details regarding the financial terms or implications of the agreement.
When was the agreement officially entered into?
The agreement was entered into on August 15, 2024, which is the date of the earliest event reported.
Is this agreement related to any specific drug development or commercialization efforts?
The filing does not provide information to determine if the agreement is related to specific drug development or commercialization efforts.
Filing Stats: 528 words · 2 min read · ~2 pages · Grade level 13 · Accepted 2024-08-16 16:04:13
Key Financial Figures
- $0.01 — nge on which registered Common Stock, $0.01 Par Value Per Share VRTX The Nasdaq G
Filing Documents
- vrtx-20240815.htm (8-K) — 22KB
- 0000875320-24-000207.txt ( ) — 143KB
- vrtx-20240815.xsd (EX-101.SCH) — 2KB
- vrtx-20240815_lab.xml (EX-101.LAB) — 21KB
- vrtx-20240815_pre.xml (EX-101.PRE) — 12KB
- vrtx-20240815_htm.xml (XML) — 3KB
01. Entry into a Material Definitive Agreement
Item 1.01. Entry into a Material Definitive Agreement. On August 15, 202 4, Vertex Pharmaceuticals Incorporated, a Massachusetts corporation ("Vertex"), and SNH Seaport LLC, a Delaware limited liability company, entered into amendments (the "Headquarters Lease Amendments") to Vertex's leases of 50 Northern Avenue, Boston, MA, dated May 5, 2011 (the "50 Northern Avenue Lease") and 11 Fan Pier Boulevard, Boston, MA, dated May 5, 2011 (together with the 50 Northern Avenue Lease, the "Headquarters Leases") pursuant to which Vertex leases a combined approximately 1.1 million square feet of office and laboratory space in two buildings. The Headquarters Lease Amendments extend the terms of the Headquarters Leases from December 2028 (subject to our option to extend the terms by ten years) until June 30, 2044, after which we have the option to extend for up to two additional ten-year periods. The foregoing description of the Headquarters Lease Amendments is only a summary of the material terms of such amendments, does not purport to be complete, and is qualified in its entirety by such amendments, which will be filed with a subsequent Quarterly Report on Form 10-Q.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. VERTEX PHARMACEUTICALS INCORPORATED (Registrant) Date: August 16, 2024 /s/ Jonathan Biller Jonathan Biller Executive Vice President, Chief Legal Officer